KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) FCF Margin: 2017-2025

Historic FCF Margin for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to 13.53%.

  • Amneal Pharmaceuticals' FCF Margin fell 424.00% to 13.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.01%, marking a year-over-year decrease of 93.00%. This contributed to the annual value of 8.70% for FY2024, which is 393.00% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its FCF Margin stood at 13.53% for Q3 2025, which was up 60.74% from 8.42% recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year FCF Margin high stood at 27.65% for Q1 2021, and its period low was -23.34% during Q2 2022.
  • Over the past 3 years, Amneal Pharmaceuticals' median FCF Margin value was 11.25% (recorded in 2023), while the average stood at 9.65%.
  • Its FCF Margin has fluctuated over the past 5 years, first slumped by 4,790bps in 2021, then surged by 2,612bps in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' FCF Margin (Quarterly) stood at 8.52% in 2021, then tumbled by 1,422bps to -5.70% in 2022, then spiked by 2,612bps to 20.42% in 2023, then crashed by 633bps to 14.09% in 2024, then crashed by 424bps to 13.53% in 2025.
  • Its FCF Margin was 13.53% in Q3 2025, compared to 8.42% in Q2 2025 and -0.83% in Q1 2025.